


#6/I.D.S

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/017,995	ATTY. DOCKET NO.: C01037.70025.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: December 14, 2001	
		APPLICANT: Robert L. Bratzler	
		GROUP ART UNIT: 1645	EXAMINER: Not yet assigned
Sheet	of 3		


U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		
<i>mm</i>	A1	5,663,153		Hutcherson, <i>et al.</i>	09-02-1997
<i>mm</i>	A2	5,723,335		Hutcherson, <i>et al.</i>	03-03-1998
<i>mm</i>	A3	6,030,955		Stein, <i>et al.</i>	02-29-2000
<i>mm</i>	A4	6,194,388	B1	Krieg, <i>et al.</i>	02-27-2001
<i>mm</i>	A5	6,207,646	B1	Krieg, <i>et al.</i>	03-27-2001
<i>mm</i>	A6	6,214,806	B1	Krieg, <i>et al.</i>	04-10-2001
<i>mm</i>	A7	6,218,371	B1	Krieg, <i>et al.</i>	04-17-2001
<i>mm</i>	A8	6,239,116	B1	Krieg, <i>et al.</i>	05-29-2001
<i>mm</i>	A9	US 2001/0021772	A1	Uhlmann, <i>et al.</i>	09-13-2001
<i>mm</i>	A10	6,339,068	B1	Davis, <i>et al.</i>	01-15-2002
<i>mm</i>	A11	6,406,705	B1	Davis, <i>et al.</i>	06-18-2002

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
<i>mm</i>	B1	EP	0 302 758	B1	Androphy, <i>et al.</i>		
<i>mm</i>	B2	EP	0 468 520	A3	Tokunaga, <i>et al.</i>		
<i>mm</i>	B3	WO	92/21353	A1	Arnold, <i>et al.</i>		
<i>mm</i>	B4	WO	94/19945	A1	Draper, <i>et al.</i>		
<i>mm</i>	B5	WO	95/05853	A1	Carson, <i>et al.</i>		
<i>mm</i>	B6	WO	95/26204	A1	Hutcherson, <i>et al.</i>		
<i>mm</i>	B7	WO	96/02555	A1	Krieg, <i>et al.</i>		
<i>mm</i>	B8	WO	97/28259	A1	Carson, <i>et al.</i>		
<i>mm</i>	B9	WO	98/16247	A1	Carson, <i>et al.</i>		
<i>mm</i>	B10	WO	98/18810	A1	Krieg, <i>et al.</i>		
<i>mm</i>	B11	WO	98/32462	A1	Wagner, <i>et al.</i>		
<i>mm</i>	B12	WO	98/40100	A1	Davis, <i>et al.</i>		
<i>mm</i>	B13	WO	98/55495	A2	Schwartz, <i>et al.</i>		
<i>mm</i>	B14	WO	98/55609	A1	Ray, <i>et al.</i>		
<i>mm</i>	B15	WO	01/02007	A1	Raz, <i>et al.</i>		
<i>mm</i>	B16	WO	01/12223	A2	Van Nest, <i>et al.</i>		
<i>mm</i>	B17	WO	99/55743	A1	Chen, <i>et al.</i>		
<i>mm</i>	B18	WO	99/11275	A2	Ray, <i>et al.</i>		

RECEIVED
NOV 05 2002
TECH CENTER 160012900

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/017,995	ATTY. DOCKET NO.: C01037.70025.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: December 14, 2001	
		APPLICANT: Robert L. Bratzler	
		GROUP ART UNIT: 1645	EXAMINER: Not yet assigned
Sheet	3		


OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>mm</i>	C1	Azuma, et al., Kekkau, Vol. 67., No. 9, pp. 625-631, (45-55), 1992 - Abstract	
<i>mm</i>	C2	Blaxter, et al., Molecular and Biochemical Parasitology, Vol. 77, pp. 77-93, 1996	
<i>mm</i>	C3	Branda, et al., Journal of Laboratory Clinical Medicine, Vol. 128, No. 3, pp. 329-338, 1996	
<i>mm</i>	C4	Brunner, et al., Journal of Immunology, Vol 165, pp. 6278-6286, 2000	
<i>mm</i>	C5	Chace, et al., Clinical Immunology and Immunopathology, Vol. 68, No. 3, pp. 327-332, 1993	
<i>mm</i>	C6	Chu, et al., Journal of Experimental Medicine, Vol. 186, No. 10, pp. 1623-1631, 1997	
<i>mm</i>	C7	Cowdery, et al., Journal of Immunology, Vol. 156, Vol. 12, pp. 4570-4575, 1996	
<i>mm</i>	C8	Davis, et al., Journal of Immunology, Vol. 160, No. 2, pp. 870-876, 1998	
<i>mm</i>	C9	Davis, et al., Current Opinion in Biotechnology, Vol. 8, No. 5, pp. 635-640, 1997	
<i>mm</i>	C10	Elkins, et al., Journal of Immunology, Vol. 162, pp. 2291-2298, 1999	
<i>mm</i>	C11	Halpern, Cellular Immunology, Vol. 167, No. 1, pp. 72-78, 1996	
<i>mm</i>	C12	Hartmann, et al., Proc. National Academy Science, Vol. 96, pp. 9305-9310, 1999	
<i>mm</i>	C13	Horner, et al., Springer Seminar Immunopathology, Vol. 22, Nos. 1-2, pp. 133-146, 2000	
<i>mm</i>	C14	Huang, et al., Infection and Immunity, Vol. 67, No. 12, pp. 6257-6263, 1999	
<i>mm</i>	C15	Jakob, et al., Journal of Immunology, Vol. 161, No. 6, pp. 3042-3049, 1998	
<i>mm</i>	C16	Jakob, et al., International Archives Allergy Immunology, Vol. 118, Nos. 2-4, pp. 457-461, 1999	
<i>mm</i>	C17	Hartmann and Krieg, Journal of Immunology, Vol 164, pg. 944, 2000	
<i>mm</i>	C18	Hartmann, et al., Journal of Immunology, Vol. 164, pg. 1617, 2000	
<i>mm</i>	C19	Hartmann and Krieg, Gene Therapy, Vol. 6, pp. 893-903, 1999	
<i>mm</i>	C20	Kataoka, et al., Japanese Journal of Cancer Research, Vol. 83, pp. 244-247, 1992	
<i>mm</i>	C21	Kataoka, et al., Japanese Journal Medical Science Biology, Vol. 43, pp. 171-189, 1990	
<i>mm</i>	C22	Kimura, et al., Journal of Biochemistry, Vol. 116, No. 5, pp. 991-994, 1994	
<i>mm</i>	C23	Klinman, et al., Journal of Immunology, Vol. 158, No. 8, pp. 3635-3639, 1997	
<i>mm</i>	C24	Klinman, et al., Proc. National Academy Science USA, Vol. 93, No. 7, pp. 2879-2883, 1996	
<i>mm</i>	C25	Klinman, et al., Immunity, Vol. 11, pp. 123-129, 1999	
<i>mm</i>	C26	Krieg, Journal of Laboratory Clinical Medicine, Vol. 128, No. 2, pp. 128-133, 1996	
<i>mm</i>	C27	Krieg, et al., Anti-Sense and Nucleic Acid Drug Development, Vol. 6, No. 2, pp. 133-139, 1996	
<i>mm</i>	C28	Iho, et al., Journal of Immunology, Vol. 163, pg. 3642, 1999	
<i>mm</i>	C29	Krieg, et al., Nature, Vol. 374, pp. 546-549, 1995	
<i>mm</i>	C30	Kuramoto, et al., Japanese Journal of Cancer Research, Vol. 83, pp. 1128-1131, 1992	
<i>mm</i>	C31	Kranzer, et al., Immunology, Vol. 99, pg. 170, 2000	
<i>mm</i>	C32	Krieg, et al., Pharmacology and Therapeutics, Vol. 84, pg. 113, 1999	
<i>mm</i>	C33	Kuramoto, International Immunopharmacology, Vol. 14, No. 5, pp. 773-782, 1992	
<i>mm</i>	C34	Lipford, et al., European Journal of Immunology, Vol. 27, No. 9, pp. 2340-2344, 1997	
<i>mm</i>	C35	Lipford, et al., Trends in Microbiology, Vol. 6, No. 12, pp. 496-500, 1998	
<i>mm</i>	C36	Liu, et al., Blood, Vol. 92, No. 10, pp. 3730-3736, 1998	
<i>mm</i>	C37	Mastrangelo, et al., Seminars in Oncology, Vol. 23, No. 1, pp. 4-21, 1996	
<i>mm</i>	C38	Parker, et al. Cancer Gene Therapy, Vol. 3, pg. 175, 1996	
<i>mm</i>	C39	Sato, et al., Science, Vol. 273, pp. 352-354, 1996	
<i>mm</i>	C40	Shimada, et al., JNCI, Vol. 74, No. 3, pp. 681-688, 1985	
<i>mm</i>	C41	Stull, et al., Pharmaceutical Research, Vol. 12, No. 4, pp. 465-483, 1995	

TECH CENTER 160012900

NOV 05 2002

RECEIVED

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 10/017,995	ATTY. DOCKET NO.: C01037.70025.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: December 14, 2001	
		APPLICANT: Robert L. Bratzler	
		GROUP ART UNIT: 1645	EXAMINER: Not yet assigned
Sheet	3		

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>mm</i>	C42	Tokunaga, et al., Microbiology Immunology, Vol. 36, No. 1, pp. 55-66, 1992	
<i>mm</i>	C43	Vil'ner, et al. Antibiotiki, 27(11):827-30, 1982. Abstract	
<i>mm</i>	C44	Vil'ner, et al. Antibiotiki 29(6):450-3, 1984. Abstract	
<i>mm</i>	C45	Vil'ner, et al. Vopr. Virusol., 30(3):337-340, 1985. Abstract	
<i>mm</i>	C46	Vil'ner, et al. Vopr. Virusol. 31(6):697-700, 1986. Abstract	
<i>mm</i>	C47	Vil'ner, et al. Vopr. Virusol. 33(3):331-35, 1988. Abstract	
<i>mm</i>	C48	Wooldridge, et al., Blood, Vol. 89, No. 8, pp. 2994-2998, 1997	
<i>mm</i>	C49	Yamamoto, et al., Microbiology Immunology, Vol. 36, No. 9, pp. 983-997, 1992	
<i>mm</i>	C50	Yamamoto, et al., Kekkaku, Vol. 69, No. 9, 571-574, 1994	
<i>mm</i>	C51	Yaswen, et al., Anti-Sense Research and Development, Vol. 3, No. 1, pp. 67-77, 1993	
<i>mm</i>	C52	Yi, et al., Journal of Immunology, Vol. 157, pp. 5394-5402, 1996	
<i>mm</i>	C53	Zheng, M. et al., Proc. Natl. Acad. Sci. USA, 2002, 99(13), 8944-8949.	
<i>mm</i>	C54	Constant, et al., Annual Review of Immunology, Vol. 15, pp. 297-322, 1997	
<i>mm</i>	C55	Loke, et al., Current Topics in Microbiology and Immunology, Vol. 141, pp. 282, 1988	
<i>mm</i>	C56	Peterson, et al., Biochemical Pharmacology, Vol. 47, No. 1, pp. 127-128, 1994	
<i>mm</i>	C57	Tokunaga, et al. JNCI, Vol. 72, pp. 955-962, 1984	
<i>mm</i>	C58	Wooldridge, et al., Proc. Amer. Assoc. for Cancer Research, 3253, Vol. 37, pp. 477, 1966 Abstract	

RECEIVED
 NOV 05 2002
 TECH CENTER 1600 2900

EXAMINER: <i>MM Mearnsfield</i>	DATE CONSIDERED: 3/9/04
---------------------------------	-------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



#7 / SUPPL.
I.D.S.

FORM 150-1449/A and 55 (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 10/017,995	ATTY. DOCKET NO.: C01037.70025.US
	FILING DATE: December 14, 2001	CONFIRMATION NO.: 7158
	APPLICANT: Robert L. Bratzler	
	GROUP ART UNIT: 1645	EXAMINER: Not yet assigned
Sheet		

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
<i>mm</i>	A12	6,030,955		Stein, et al.	02-29-2000

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
<i>mm</i>	B18	WO	95/11687	A	Dzau	05-04-1995	
<i>mm</i>	B19	WO	95/17507	A	Biognostik GES, et al.	06-29-1995	
<i>mm</i>	B20	WO	99/51259		Univ Iowa Res Found	10-14-1999	
<i>mm</i>	B21	WO	99/58118		CpG Immunopharmaceuticals GmbH, et	11-18-1999	
<i>mm</i>	B22	WO	00/06588		University of Iowa Research Foundation	02-10-2000	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>mm</i>	C59	KRIEG, A.M., et al. "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs." Proc. Natl Acad Sci USA, 95:1631-1636 (October 1998).	

EXAMINER <i>M. M. Wignall</i>	DATE CONSIDERED <i>3/9/04</i>
-------------------------------	-------------------------------


#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

#8

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet <input type="checkbox"/>	APPLICATION NO.: 10:017,951	ATTY. DOCKET NO.: C01037.70025.US
	FILING DATE: December 14, 2001	CONFIRMATION NO.: 7158
	APPLICANT: Robert L. Bratzler	
	GROUP ART UNIT: 1445	EXAMINER: Not yet assigned



U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
mm	C60	LIPFORD, G., et al, "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines." <i>Eur. J. Immunol.</i> , 1997, 27:3420-3426.	

EXAMINER: <i>N. M. Hunsfield</i>	DATE CONSIDERED: 3/9/04
---	--------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

RECEIVED
MAR 07 2003
TECH CENTER 1600/2900